Business Description
Poxel S.A. is a French drug development company focused on finding new medicines for type 2 diabetes, liver disease, and rare metabolic conditions. Founded in 2009 and based in Lyon, its most advanced product is TWYMEEG (Imeglimin), an oral diabetes treatment already approved in Japan and commercialized through a partnership with Sumitomo Pharma. The company has several other drug candidates in clinical trials targeting liver conditions such as non-alcoholic steatohepatitis, developed in collaboration with partners including DeuteRx and Enyo Pharma.
